Search Results - Parodi A

IL-1 beta receptor antagonist efficacy in the treatment of idiopathic recurrent pericarditis by Picco P, Traverso F, Brisca G, Parodi A, Loy A, Gattorno M, Martini A

Connect to this object online.

Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes by Torre E, Bruno GM, Di Matteo S, Martinotti C, Oselin M, Valentino MC, Parodi A, Bottaro LC, Colombo GL

Connect to this object online.

Comparison of physician's, parent's and patient's global ratings made on linear or 21-circle visual analogue scales (VAS) in juvenile idiopathic arthritis (JIA) by Dalprà S, Verazza S, Ferrari C, Parodi A, Davì S, Schiappapietra B, Consolaro A, Filocamo G, Viola S, Martini A, Ravelli A

Connect to this object online.

Etanercept efficacy in the treatment of chronic isolated inflammatory coxitis by Parodi A, Picco P, Malattia C, Davì S, Dalprà S, Traverso F, Ponti MC, Buoncompagni A, Loy A, Viola S, Martini A

Connect to this object online.

Quantitative assessment of synovitis in juvenile idiopathic arthritis using Dynamic Contrast-Enhanced Magnetic Resonance Imaging by Malattia C, Damasio MB, Basso C, Verri A, Magnaguagno F, Parodi A, Viola S, Ravelli A, Tomà P, Martini A

Connect to this object online.

The diagnostic role of hyperferritinemia in a tertiary care pediatric rheumatology setting by Sala I, Trail L, Lattanzi B, Solari N, Palmisani E, Parodi A, Malattia C, Buoncompagni A, Loy A, Martini A, Ravelli A

Connect to this object online.

Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study by Talamonti M, Russo F, Malara G, Hansel K, Papini M, Cattaneo A, Parodi A, Chiricozzi A, Malagoli P, Bardazzi F, Brazzelli V, Dapavo P, Gisondi P, Zane C, Potenza C, Cantoresi F, Fargnoli MC, Trevisini S, Brianti P, Pescitelli L, Gigante G, Bartezaghi M, Caputo L, Aloisi E, Costanzo A

Connect to this object online.

Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study by Russo F, Galluzzo M, Stingeni L, Persechino S, Zichichi L, Conti A, Giofrè C, Dini V, Vispi M, Atzori L, Cattaneo A, Parodi A, Bardazzi F, Stinco G, Dapavo P, Girolomoni G, Musumeci ML, Papini M, Venturini M, Dastoli S, Di Nuzzo S, Fargnoli MC, Pagnanelli G, Bernardini N, Gambini DM, Malagoli P, Mazzatenta C, Peris K, Zalaudek I, Fabbrocini G, Loconsole F, Vassallo C, Pietroleonardo L, Prignano F, Franchi C, Offidani AM, Bonifati C, Di Lernia V, Gigante G, Bartezaghi MS, Franchi M, Ursoleo P, Aloisi E

Connect to this object online.